| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Riihimäki M, Hemminki A, Sundquist J, et al. Patterns of metastasis in colon and rectal cancer [J]. Sci Rep, 2016, 6: 29765.
|
| [3] |
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3): 263-267.
|
| [4] |
Sánchez-hidalgo JM, Rodríguez-ortiz L, Arjona-sánchez Á, et al. Colorectal peritoneal metastases: Optimal management review[J]. World J Gastroenterol, 2019, 25(27): 3484-3502.
|
| [5] |
Yurttas C, Hoffmann G, Tolios A, et al. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer[J]. J Clin Med, 2018, 7(12): 567.
|
| [6] |
Capobianco A, Cottone L, Monno A, et al. The peritoneum: healing, immunity, and diseases[J]. J Pathol, 2017, 243(2): 137-147.
|
| [7] |
Cortés-guiral D, Hübner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies[J]. Nat Rev Dis Primers, 2021, 7(1): 91.
|
| [8] |
Kojima M, Higuchi Y, Yokota M, et al. Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis[J]. PLoS One, 2014, 9(2): e88018.
|
| [9] |
MikuŁa-pietrasik J, Uruski P, Tykarski A, et al. The peritoneal "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases[J]. Cell Mol Life Sci, 2018, 75(3): 509-525.
|
| [10] |
Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective[J]. World J Gastroenterol, 2016, 22(28): 6362-6372.
|
| [11] |
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review[J]. JAMA, 2021, 325(7): 669-685.
|
| [12] |
中国医师协会结直肠肿瘤专业委员会腹膜肿瘤专委会. 结直肠癌腹膜转移诊治中国专家共识(2022版)[J/OL]. 中华结直肠疾病电子杂志, 2022, 11(4): 265-271.
|
| [13] |
Ganesh K, Stadler Z K, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
|
| [14] |
Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 [J]. J Clin Oncol, 2020, 38(1): 11-19.
|
| [15] |
Overman MJ, Mcdermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191.
|
| [16] |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| [17] |
Network NCC. (NCCN) Clinical Practice Guidelines in Oncology. Colon Cancer, Version 2. 2022. [J]. NCCN, 2022.
|
| [18] |
Berek JS, Knapp RC, Hacker NF, et al. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum[J]. Am J Obstet Gynecol, 1985, 152(8): 1003-1010.
|
| [19] |
Berek JS. Intraperitoneal adoptive immunotherapy for peritoneal cancer[J]. J Clin Oncol, 1990, 8(10): 1610-1612.
|
| [20] |
Steis RG, Urba WJ, Vandermolen LA, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity [J]. J Clin Oncol, 1990, 8(10): 1618-1629.
|
| [21] |
Nash AM, Jarvis MI, Aghlara-fotovat S, et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors [J]. Sci Adv, 2022, 8(9): eabm1032.
|
| [22] |
Miller AM, Lemke-miltner CD, Blackwell S, et al. Intraperitoneal CMP-001: A novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer [J]. Ann Surg Oncol, 2021, 28(2): 1187-1197.
|
| [23] |
Jiang T, Zhang H, Li Y, et al. Intraperitoneal injection of class A TLR9 agonist enhances anti-PD-1 immunotherapy in colorectal peritoneal metastases [J]. JCI Insight, 2022, 7(20): e160063.
|
| [24] |
Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer[J]. J Immunother Cancer, 2021, 9(6): e002195.
|
| [25] |
Zhao Z, Zheng L, Chen W, et al. Delivery strategies of cancer immunotherapy: recent advances and future perspectives [J]. J Hematol Oncol, 2019, 12(1): 126.
|
| [26] |
Saxena M, Van Der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360-378.
|
| [27] |
Harrington K, Freeman DJ, Kelly B, et al. Optimizing oncolytic virotherapy in cancer treatment [J]. Nat Rev Drug Discov, 2019, 18(9): 689-706.
|
| [28] |
Alkayyal AA, Tai LH, Kennedy MA, et al. NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an Il12-expressing maraba virus cellular vaccine[J]. Cancer Immunol Res, 2017, 5(3): 211-221.
|
| [29] |
Lee YS, Lee WS, Kim CW, et al. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer[J]. J Immunother Cancer, 2020, 8(2): e000857.
|
| [30] |
Lauer UM, Schell M, Beil J, et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis[J]. Clin Cancer Res, 2018, 24(18): 4388-4398.
|
| [31] |
Zamarin D, Odunsi K, Zsiros E, et al. Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results [J]. Journal of Clinical Oncology, 2022, 40(suppl. 16): 2600.
|
| [32] |
Pouget JP, Navarro-teulon I, Bardiès M, et al. Clinical radioimmunotherapy--the role of radiobiology [J]. Nat Rev Clin Oncol, 2011, 8(12): 720-734.
|
| [33] |
Kinuya S, Li XF, Yokoyama K, et al. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy[J]. Cancer Sci, 2003, 94(7): 650-654.
|
| [34] |
Schoffelen R, Van Der Graaf WT, Sharkey RM, et al. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer [J]. J Nucl Med, 2012, 53(12): 1926-1932.
|
| [35] |
Chandler CS, Bell MM, Chung SK, et al. Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis [J]. Mol Cancer Ther, 2022, 21(1): 125-137.
|
| [36] |
Hallqvist A, Bergmark K, Bäck T, et al. Intraperitoneal α-emitting radioimmunotherapy with (211)at in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations [J]. J Nucl Med, 2019, 60(8): 1073-1079.
|
| [37] |
Modak S, Zanzonico P, Grkovski M, et al. B7H3- directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study [J]. J Clin Oncol, 2020, 38(36): 4283-4291.
|
| [38] |
Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial [J]. Int J Cancer, 2010, 127(9): 2209-2221.
|
| [39] |
Ströhlein MA, Lordick F, Rüttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial [J]. Onkologie, 2011, 34(3): 101-108.
|
| [40] |
Ströhlein MA, Heiss MM, Jauch KW. The current status of immunotherapy in peritoneal carcinomatosis [J]. Expert Rev Anticancer Ther, 2016, 16(10): 1019-1027.
|
| [41] |
Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa phase 1 trial [J]. Ann Surg Oncol, 2017, 24(7): 1916-1922.
|
| [42] |
Frøysnes IS, Andersson Y, Larsen SG, et al. ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis [J]. Eur J Surg Oncol, 2021, 47(1): 134-138.
|
| [43] |
Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy [J]. Cancer Cell, 2020, 38(4): 473-488.
|
| [44] |
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia [J]. N Engl J Med, 2014, 371(16): 1507-1517.
|
| [45] |
Katz SC, Point GR, Cunetta M, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery [J]. Cancer Gene Ther, 2016, 23(5): 142-148.
|
| [46] |
Qian S, Villarejo-campos P, García-olmo D. The role of CAR-T cells in peritoneal carcinomatosis from gastric cancer: rationale, experimental work, and clinical applications[J]. J Clin Med, 2021, 10(21): 5050.
|
| [47] |
Ang WX, Li Z, Chi Z, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis [J]. Oncotarget, 2017, 8(8): 13545-13559.
|
| [48] |
Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients [J]. Mol Ther, 2019, 27(6): 1114-1125.
|
| [49] |
Li Z, Chi Z, Ang WX, et al. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR [J]. Immunotherapy, 2020, 12(10): 733-748.
|
| [50] |
Newick K, O'brien S, Moon E, et al. CAR T cell therapy for solid tumors[J]. Annu Rev Med, 2017, 68(1): 39-52.
|